Paxerol™ Introduction - An Unmet Medical NeedNocturia, the frequent need to urinate at night, afflicts 2.2B people. Our patented drug to prevent nocturia is a fixed dose extended release combination of safe drugs that reduces nocturia by 33-100%. We are seeking $2.6M to launch the drug in Europe Q1…
Paxerol™ Introduction - An Unmet Medical Need
Nocturia, the frequent need to urinate at night, afflicts 2.2B people. Our patented drug to prevent nocturia is a fixed dose extended release combination of safe drugs that reduces nocturia by 33-100%. We are seeking $2.6M to launch the drug in Europe Q1 2015 and complete one clinical trial before licensing our patents to a big pharma company in mid-2015. Since we are using low doses of known safe drugs for a new purpose, the FDA approval path is very fast.
Nocturia, a sometimes deadly condition, causes insomnia, fatigue, depression, and lower quality of life. It is linked to higher rates of heart disease, stroke, brain damage, and sometimes deadly hip fractures. In the US alone, exhaustion due to nocturia causes over $60B per year in lost work time. Twenty-five percent (25%) of nursing home operating costs are the result of urinary incontinence. No drug on the market today solves the problem of low nocturnal bladder capacity, the major issue for 76% of nocturia sufferers.
Team (1)
Sectors Wellesley Pharmaceuticals serves:
Health Care
Life Sciences
Join Axial's Private M&A Platform
Wellesley Pharmaceuticals connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
